Trials / Recruiting
RecruitingNCT07317414
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
A Randomized Clinical Trial Exploring β-alanine as an Adjunct to First-line Immunotherapy in Advanced Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 158 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective, randomized controlled study on nutritional support and metabolic regulation. It assesses the safety, compliance, and improvement of metabolic/physical-related indicators when using β-alanine within the specified dose range as dietary supplementation, in addition to the standard first-line treatment. The anti-tumor efficacy (ORR, PFS, OS) is the exploratory endpoint.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab combined with bevacizumab combined with β- alanine | Atezolizumab (Tecentriq®) + Bevacizumab (Avastin®)+β- alanine |
| DRUG | Atezolizumab combined with bevacizumab | Atezolizumab (Tecentriq®) + Bevacizumab (Avastin®) |
Timeline
- Start date
- 2025-12-24
- Primary completion
- 2028-12-05
- Completion
- 2030-12-05
- First posted
- 2026-01-05
- Last updated
- 2026-01-05
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07317414. Inclusion in this directory is not an endorsement.